Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95175
Title:
Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients.
Authors:
Robson, Helen; Anderson, Elizabeth; James, Roger D; Schofield, Philip F
Abstract:
Members of the transforming growth factor beta (TGF-beta family, in particular TGF-beta 1, are some of the most potent inhibitory growth factors in a variety of cell types. Resistance to TGF-beta 1-induced growth inhibition is frequently observed in colorectal carcinomas and is associated with tumour progression. Perturbations of TGF-beta 1 expression and function, therefore, may contribute to the loss of some constraints on tumour cell growth. In this study we have examined the expression of TGF-beta 1 and its precursor latency-associated peptide (LAP)-TGF-beta in human colorectal tumours using immunohistochemical techniques. In 86% of the tumours the LAP-TGF-beta complex was present in both the stromal and epithelial cells, whereas the mature TGF-beta 1 peptide was expressed in the glandular epithelium of 58.3% of these tumours. Intense staining for TGF-beta 1 was positively associated with advanced Dukes' stage. Furthermore, there was a significant correlation between the presence of TGF-beta 1 in the tumours and a shorter post-operative survival. This was most significant in a subgroup of patients who had received only a palliative operation. These results suggest that TGF-beta 1 expression may be useful as an independent prognostic indicator for a subgroup of patients who have a particularly poor prognosis.
Affiliation:
Tumour Biochemistry Department, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. 1996, 74 (5):753-8 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Sep-1996
URI:
http://hdl.handle.net/10541/95175
PubMed ID:
8795578
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRobson, Helenen
dc.contributor.authorAnderson, Elizabethen
dc.contributor.authorJames, Roger Den
dc.contributor.authorSchofield, Philip Fen
dc.date.accessioned2010-03-29T13:52:53Z-
dc.date.available2010-03-29T13:52:53Z-
dc.date.issued1996-09-
dc.identifier.citationTransforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. 1996, 74 (5):753-8 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid8795578-
dc.identifier.urihttp://hdl.handle.net/10541/95175-
dc.description.abstractMembers of the transforming growth factor beta (TGF-beta family, in particular TGF-beta 1, are some of the most potent inhibitory growth factors in a variety of cell types. Resistance to TGF-beta 1-induced growth inhibition is frequently observed in colorectal carcinomas and is associated with tumour progression. Perturbations of TGF-beta 1 expression and function, therefore, may contribute to the loss of some constraints on tumour cell growth. In this study we have examined the expression of TGF-beta 1 and its precursor latency-associated peptide (LAP)-TGF-beta in human colorectal tumours using immunohistochemical techniques. In 86% of the tumours the LAP-TGF-beta complex was present in both the stromal and epithelial cells, whereas the mature TGF-beta 1 peptide was expressed in the glandular epithelium of 58.3% of these tumours. Intense staining for TGF-beta 1 was positively associated with advanced Dukes' stage. Furthermore, there was a significant correlation between the presence of TGF-beta 1 in the tumours and a shorter post-operative survival. This was most significant in a subgroup of patients who had received only a palliative operation. These results suggest that TGF-beta 1 expression may be useful as an independent prognostic indicator for a subgroup of patients who have a particularly poor prognosis.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshChi-Square Distribution-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPeptide Fragments-
dc.subject.meshPrognosis-
dc.subject.meshProtein Precursors-
dc.subject.meshProteins-
dc.subject.meshSurvival Rate-
dc.subject.meshTransforming Growth Factor beta-
dc.subject.meshTransforming Growth Factor beta1-
dc.subject.meshTumor Markers, Biological-
dc.titleTransforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients.en
dc.typeArticleen
dc.contributor.departmentTumour Biochemistry Department, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.